{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:59:04Z","timestamp":1784602744061,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Canine multiple myeloma (MM) is typically treated with melphalan chemotherapy. A protocol with repeated 10\u2010day cyclical dosing of melphalan has been used at our institution but has not been described in the literature. Our objectives were to describe the outcome and adverse events of this protocol in a retrospective case series. We hypothesised the cyclical 10\u2010day protocol would have similar outcomes compared to other reported chemotherapy protocols. Dogs diagnosed with MM that received melphalan treatment at Cornell University Hospital for Animals were identified through a database search. Records were retrospectively reviewed. Seventeen dogs met inclusion criteria. Lethargy was the most common presenting complaint. The median duration of clinical signs was 53\u2009days (range, 2\u2013150\u2009days). Seventeen dogs had hyperglobulinemia with 16\/17 having monoclonal gammopathies. Sixteen dogs had bone marrow aspiration and cytology performed at initial diagnosis and plasmacytosis was diagnosed in all. Based on serum globulin concentrations, 10 of 17 dogs (59%) achieved complete response (CR), and 3 dogs (18%) achieved partial response (PR), for an overall response rate of 76%. The median overall survival time was 512\u2009days (range, 39\u20131065). Retinal detachment (<jats:italic>n<\/jats:italic>\u2009=\u20093) and maximum response of CR\/PR (<jats:italic>n<\/jats:italic>\u2009=\u200913) were associated with overall survival on multivariate analysis (<jats:italic>p<\/jats:italic>\u2009=\u2009.045 and .046, respectively). Adverse events were minimal with diarrhoea being the most reported (<jats:italic>n<\/jats:italic>\u2009=\u20096). This cyclical 10\u2010day protocol was better\u2010tolerated with fewer adverse events than with other reported chemotherapy protocols, but response rate was also lower, likely due to a lower dosing intensity.<\/jats:p>","DOI":"10.1111\/vco.12916","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T08:14:11Z","timestamp":1686125651000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cyclical 10\u2010day dosing of melphalan for canine multiple myeloma"],"prefix":"10.1111","volume":"21","author":[{"given":"Lucy","family":"Teddy","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Cornell University College of Veterinary Medicine  Ithaca New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skylar R.","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Cornell University College of Veterinary Medicine  Ithaca New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Cornell University Hospital for Animals Cornell University College of Veterinary Medicine  Ithaca New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-2118","authenticated-orcid":false,"given":"Kelly R.","family":"Hume","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Cornell University College of Veterinary Medicine  Ithaca New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-0279(77)50010-X"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15084"},{"key":"e_1_2_9_4_1","first-page":"665","volume-title":"Withrow and MacEwen's Small Animal Clinical Oncology","author":"Vail D","year":"2013"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.20.04145-2"},{"issue":"11","key":"e_1_2_9_6_1","first-page":"1288","article-title":"Prognostic factors for multiple myeloma in the dog","volume":"188","author":"Matus RE","year":"1986","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2019.07.006"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/1746-6148-10-30"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15967"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12677"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0388-5"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0100"},{"issue":"10","key":"e_1_2_9_13_1","first-page":"1300","article-title":"Multiple myeloma in the dog","volume":"153","author":"Osborne CA","year":"1968","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ani12070913"},{"issue":"1","key":"e_1_2_9_15_1","first-page":"1","article-title":"Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group","volume":"28","author":"Pozzi C","year":"1987","journal-title":"Clin Nephrol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S153146"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012678"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.13805"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12301"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T06:40:10Z","timestamp":1692081610000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1111\/vco.12916"],"URL":"https:\/\/doi.org\/10.1111\/vco.12916","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"2023-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}